Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
June 10, 2023 10:47 ET | Nkarta, Inc.
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation...
Celldex Logo.jpg
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 10, 2023 10:45 ET | Celldex Therapeutics, Inc.
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 24, 55% of all patients with CSU in the...
EHA2023 | 亘喜生物公布FasTCAR-T GC012F治疗B-NHL的最新临床研究成果,总体应答率高达100%
June 10, 2023 10:30 ET | Gracell Biotechnologies Inc.
CD19/BCMA双靶点FasTCAR-T GC012F展现优异疗效数据:总体应答率(ORR)高达100%,在第6个月时的完全缓解率(CR)为67%,所有患者均为弥漫性大B细胞淋巴瘤(DLBCL)亚型患者 GC012F治疗复发/难治性多发性骨髓瘤(RRMM)以及供者来源CAR-T GC007g治疗B-ALL的临床数据已于6月9日在EHA2023年会上分别以学术海报形式公布 ...
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
June 10, 2023 10:30 ET | Gracell Biotechnologies Inc.
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma...
Hookipa Pharma Logo Square.png
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2023 05:00 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
onsemi to Join the Nasdaq-100 Index Beginning June 20, 2023
June 09, 2023 20:00 ET | Nasdaq, Inc.
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that onsemi (Nasdaq: ON) will become a component of the Nasdaq -100 Index® (Nasdaq: NDX), the Nasdaq -100 Equal...
The three-bedroom Ashley floor plan by LGI Homes is available at McKee Creek Village.
LGI Homes Opens New Community in Charlotte, McKee Creek Village
June 09, 2023 19:00 ET | LGI Homes, Inc.
CHARLOTTE, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) announced the company is now selling brand-new, single-family homes at McKee Creek Village. Ideally positioned in...
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
June 09, 2023 18:45 ET | Biogen Inc.
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease ...
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
June 09, 2023 18:25 ET | Allogene Therapeutics, Inc.
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous TherapiesPresentation...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023 18:00 ET | Kymera Therapeutics, Inc.
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no...